RP-1664
RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research[1][2].
Product Specifications
CAS Number
[2980682-00-4]
UNSPSC
12352211
Target
Polo-like Kinase (PLK)
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(NC2=NC(N(C3=C(C=C(C=C3F)S(C)(=O)=O)F)C)=NC(C4=CN(C=N4)C)=C2C5CC5)=NN1
Molecular Formula
C23H24F2N8O2S
Molecular Weight
514.55
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
PLK4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CASP2 And RIPK1 Domain Containing Adaptor With Death Domain Protein (CRADD) Antibody (Biotin)
CASP2 And RIPK1 Domain Containing Adaptor With Death Domain Protein (CRADD) Antibody (Biotin)
CASP2 And RIPK1 Domain Containing Adaptor With Death Domain Protein (CRADD) Antibody (Biotin)
CASP2 And RIPK1 Domain Containing Adaptor With Death Domain Protein (CRADD) Antibody (Biotin)
CASP2 And RIPK1 Domain Containing Adaptor With Death Domain Protein (CRADD) Antibody (Biotin)